Phaeochromocytomas arising in adrenal or extra-adrenal sites and paragangliomas of the head and neck, in particular of the carotid bodies, occur sporadically and also in a familial setting. In addition to mutations in RET and VHL in familial disease, germline mutations in SDHD and SDHB genes that encode subunits of mitochondrial complex II have also been associated with the development of familial phaeochromocytomas. To further investigate the role of SDHD and SDHB in the development of these tumours we determined the occurrence of germline SDHD and SDHB mutations in four patients with a family history of phaeochromocytoma with associated head and neck paraganglioma, one patient with a family history of phaeochromocytoma only and two patients with apparently sporadic extra-adrenal phaeochromocytoma, one of whom had early onset disease. Secondly, we investigated whether somatic SDHB mutations correlated with loss of heterozygosity at 1p36 in a subgroup of 11 sporadic and three MEN 2-associated RET-mutation-positive phaeochromocytomas. Novel SDHB mutations were identified in the probands from four families and two apparently sporadic cases (six of seven probands studied), including two missense mutations, a single nonsense and frameshift mutation, as well as two splice site mutations, one of which was shown to have partial penetrance resulting in 'leaky' splicing. Further, five intronic polymorphisms in SDHB were found. No SDHD mutations were identified. In addition, no somatic SDHB mutations were found in the remaining allele of the 11 sporadic adrenal phaeochromocytomas with allelic loss at 1p36 or the three MEN 2-associated RET-mutation-positive phaeochromocytomas. Therefore, we conclude that SDHB has a major role in the pathogenesis of familial phaeochromocytomas, but the possible role of SDHB in sporadic tumours showing allelic loss at 1p36 has yet to be ascertained.
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Introduction
Phaeochromocytomas are rare tumours arising in the neural crest-derived chromaffin cells of the adrenal gland, or in extra-adrenal sympathetic ganglia where they may be described as extra-adrenal phaeochromocytomas (Lack, 1997; Solcia et al., 2000) . In the familial setting, these tumours are often associated with the cancer syndromes multiple endocrine neoplasia type 2 (MEN 2; OMIM 164761), von Hippel Lindau disease (VHL; OMIM 193300) and rarely neurofibromatosis type l (NF1; OMIM 162200). Germline mutations in SDHD (11q23) and SDHB (1p36.1), encoding subunits of the mitochondrial complex II (reviewed in Benn et al., 2002) have also been associated with familial phaeochromocytoma (Astuti et al., 200la, b) . However, the molecular pathogenesis of sporadic disease remains largely unknown, although somatic mutations have been identified in VHL (2%), RET (10%) and SDHD (6% ) (Eng et al., 1995; Hofstra et al., 1996; Gimm et al., 2000) , yet none in SDHB (Astuti et al., 2001b) in these tumours. Loss of heterozygosity (LOH) studies have suggested that chromosome lp may be the site of at least two and possibly three tumour suppressor genes with a region at 1p36 being involved not only in phaeochromocytomas (Benn et al., 2000) , but also in other endocrine and neural crest-derived tumours such as neuroblastoma (Williamson et al., 1997; Caron et al., 2001 ).
Paragangliomas (PGLs) are rare tumours of the parasympathetic system occurring mainly in the carotid bodies of the head and neck, and composed of neural crest-derived chief cells (Solcia et al., 2000) . It is believed that up to 50% of these tumours occur in a familial setting (Baysal, 2001 ) and in addition to SDHB and SDHD, a third peptide SDHC of mitochondrial complex II (succinate : ubiquinone oxidoreductase) has been shown to be mutated in the germline of a single family with head and neck paraganglioma (Niemann and Mueller, 2000) . Two of the peptides of complex II (SDHA and SDHB) form the catalytic unit of the enzyme succinate dehydrogenase, which links the Krebs cycle to the electron transport chain (Scheffler, 1998) , with the other two peptides, SDHD and SDHC functioning to anchor complex II to the inner mitochondrial membrane. In addition, it has been postulated that mitochondrial complex II plays a role in oxygen sensing in the carotid body (Baysal et al., 2000) .
Germline SDHB mutations have been found in 50% of phaeochromocytoma families (without evidence of RET, VHL or SDHD mutations) with or without associated head and neck paraganglioma (Astuti et al., 2001b) , and in 20% of families with only head and neck paragangliomas (Baysal et al., 2002) . Occult germline SDHB mutations, one in a patient with head and neck tumours (Baysal et al., 2002) , and the other in a patient with phaeochromocytoma without LOH at the SDHB locus (Astuti et al., 2001b) Therefore, to further explore the putative role of mitochondrial complex II in the development of these tumours we analysed SDHD and SDHB for mutations in genomic samples from two apparently sporadic cases of extra-adrenal phaeochromocytomas and five patients with a family history of phaeochromocytoma with or without paraganglioma, and no clinical manifestations of MEN 2, VHL or NF1. In addition, we investigated whether the presence of somatic SDHB mutations correlated with LOH at 1p36 in a subgroup of 11 sporadic adrenal phaeochromocytomas and three MEN 2-associated RET-mutation-positive phaeochromocytomas, following a '2-hit' model of tumorigenesis (Knudson, 1993) .
Results
Germline mutations of SDHB were identified in six of seven probands studied (Figure 1 ). The pathology of the probands' tumours is described in Table 1 , in addition to associated tumours identified in other family members. The first missense mutation (c.137G>A; R46Q) was found in a family (F04) that has previously been reported as a case study (Lee et al., 1977) . The second missense mutation (c.194T>A; L65H) was identified in exon 2 of SDHB in a patient (F06), who also exhibited an intronic variant IVS2+3G>C, found to be on the same allele. Loss of the wild-type allele in the tumour from this patient was demonstrated in eight of eight informative loci in the region of lpter to lp34.3 which includes the SDHB locus. Analysis of cDNA prepared from fresh frozen tumour tissue from this patient revealed two fragments, the larger of 353 bp showing retention of exon 2 and the c.194T>A mutation, while the smaller of 252 bp was the result of exon 2 skipping, the 3 0 end of exon 1 being fused to the 5 0 end of exon 3, thus confirming that this aberrant 'leaky' splicing was occurring from the mutant allele. None of the three variants described here (R46Q, L65H, IVS2+3G>C) was identified in 100 normal alleles.
In addition, a novel exon 2 frameshift (c.88delC) was detected in a patient (F01) and in his mother who had not presented with disease. This frameshift caused a stop codon in exon 3, 139 nucleotides downstream and is predicted to cause a truncated protein. In a 7-year-old boy (F05) a mutation was found in exon 2 of SDHB (c.136C>T; R46X), and also in his father who had not presented with disease. A novel splice site mutation (IVS4 -1G>A) was detected in a male (F02) who first presented at 15 years and in his father who had not presented with disease. Family history had shown two affected siblings of the proband's father. A previously described mutation (c.268C>T; R90X) (Astuti et al., 2001b (Astuti et al., , 2002 was found in a family (F03) with two affected first degree relatives.
In one family, a rare novel polymorphism (IVS2 -36T>G) was found in a mutation-negative family member but not in his affected parent. The genotype frequencies for this variant in a panel of 50 normals were 94% TT and 6% TG. In another family, a rare novel polymorphism (IVS2+35G>A) (92% GG, 8% GA) was found in the proband and in his mutation-positive father. Two common novel polymorphisms were identified IVS1-111G>A (with genotype frequencies 28% GG, 48% GA and 24% AA) and IVS2+33G>A (with genotype frequencies of 80% GG, 18% GA and 2% AA) in a population of 100 normal alleles, as well as a rare novel frameshift (IVS1 -29delT) in one individual.
In three of five SDHB-positive families, we observed paternal inheritance of the SDHB mutation and maternal inheritance in one other family, resulting in a disease phenotype (Figure 2 ). While paternal inheritance of SDHB mutations has been described in families with only head and neck paragangliomas (Baysal et al., 2002) , this is the first report, to our knowledge, of paternal inheritance of SDHB mutations resulting in a disease phenotype in familial phaeochromocytomas.
LOH analysis using the polymorphism IVS1-111G>A and blood/tumour pairs of 15 patients with sporadic adrenal phaeochromocytomas, showed heterozygosity in the germline DNA in eight of 15 (53%) patients and subsequently LOH in four of eight (50%). These four tumours were then included in the SDHB mutation analysis with the seven sporadic tumours and the three RET-mutation-positive phaeochromocytomas, which had shown LOH at lpter to lp34.3 in our earlier study (Benn et al., 2000) . No SDHB mutations were found in the retained allele in any of these 14 tumours.
Discussion
Analysis of germline DNA from two patients with apparently sporadic tumours and five patients with a family history of phaeochromocytoma (adrenal or extra-adrenal) with or without associated paraganglioma showed a total of six novel mutations including one missense mutation, two nonsense mutations, one frameshift and two likely splice site mutations. In addition, five novel polymorphisms were identified and their frequency in 100 normal alleles ascertained. A previously described mutation (R90X) (Astuti et al., 2001b (Astuti et al., , 2002 was also identified in exon 3. Eleven sporadic phaeochromocytomas and three MEN 2-associated RET-mutation-positive phaeochromocytomas with LOH at chromosome 1p36 or specifically shown at the SDHB locus, were wild type at the retained SDHB allele.
Previous work by our group (Benn et al., 2000) and others (Edstro¨m et al., 2002) has indicated that specific regions of chromosomal loss on 1p, likely housing tumour suppressor genes, are associated with the development of phaeochromocytomas. Our studies of the 1pter to 1p34.3 interval suggested the involvement of at least two putative tumour suppressor genes on 1p in the pathogenesis of both sporadic and familial phaeochromocytoma. However, despite SDHB having been mapped to 1p36 (Leckschat et al., 1993) and this cohort of tumours (both sporadic and MEN 2 associated) showing LOH in this region, the finding of no somatic SDHB mutations in the retained allele indicates that somatic SDHB mutations are not involved in the development of these phaeochromocytomas. This first study of somatic SDHB mutations in a group of sporadic phaeochromocytomas with identified LOH at 1p36 could indicate that a different tumour suppressor gene at this site is involved in the development of these tumours. Alternatively, functional abrogation of SDHB might be involved via a regulatory mechanism such as methylation of the promotor region of the remaining allele. A third possibility is that SDHB haploinsufficiency alone may contribute to tumour development in these tumours. With regard to the MEN 2-related phaeochromocytomas, one study of such tumours with LOH at the VHL locus showed somatic VHL genetic alterations, suggesting that VHL may play a role in these tumours in addition to germline mutation of the RET proto-oncogene (Koch et al., 2002) . Similarly, we examined three MEN 2-associated RET-mutation-positive phaeochromocytomas with LOH at the SDHB locus and found that the remaining SDHB allele was wild type. Our data suggest that germline mutation of SDHB occurs more frequently than that of SDHD in familial phaeochromocytoma, with or without associated paraganglioma. An earlier study of eight familial phaeochromocytomas negative for RET, VHL, SDHC and SDHD found 50% of unrelated cases with germline mutations in SDHB (Astuti et al., 2001b) . In contrast, germline mutation of SDHD appears to be more prevalent in cases of familial head and neck paragangliomas, with one study of 10 families showing 50% of cases with germline SDHD mutations and only 20% with SDHB mutations (Baysal et al., 2002) . As genetic data from more families are reported, a clearer picture of possible genotype/phenotype correlations will begin to emerge.
In familial head and neck paraganglioma, maternal imprinting has been demonstrated in SDHD-mutationpositive families (Baysal et al., 2000) , but both maternal and paternal inheritance of SDHB mutations has been reported (Baysal et al., 2002) . However, in familial phaeochromocytoma with or without associated paragangliomas, only maternal inheritance resulting in the disease phenotype had been reported (Astuti et al., 2001b) . In familial phaeochromocytomas, we observed represents head and neck paraganglioma; (+/-) represents SDHB mutation carrier; (-/-) represents SDHB-mutation-negative patient paternal inheritance of the SDHB gene mutation in three families and maternal inheritance in one family. This is the first report of the paternal mode of SDHB inheritance in familial phaeochromocytomas, suggesting that neither SDHB-mutation-positive phaeochromocytoma or paraganglioma families display genomic imprinting.
In three families (F01, F02 and F05), we observed that the SDHB-mutation-positive parent of each proband had not presented with disease, yet the proband had manifested the disease at an early age (12, 15 and 7 years, respectively). This pattern of disease presentation suggests that SDHB may be a variably penetrant gene with its expression being influenced by genetic or environmental modifiers. It is possible that decreased or no expression of wild-type SDHB impairs mitochondrial complex II activity and may influence variability in age presentation. Of interest, the extra-adrenal phaeochromocytoma of F06 with two germline SDHB mutations, c.194T>A and IVS2+3G>C, and somatic loss of the corresponding wild-type allele, showed 'leaky' splicing that resulted in two abnormal transcripts. The phenomenon of ''leaky'' splicing has recently been reported in the gene encoding spastin, where mutations lead to the neurodegenerative disorder hereditary spastic paraplegia (SPG4), and may, in part, account for variable expressivity in conditions where it is found to occur (Svenson et al., 2001) . This paper highlights the importance of SDHB testing in patients presenting with phaeochromocytoma with or without associated paraganglioma disease, and in particular in families where the proband presents at a young age, but neither parent has shown evidence of disease.
Methods

Patients and samples
Firstly, peripheral blood from four patients with a family history of phaeochromocytoma with associated head and neck paraganglioma, one patient with a family history of phaeochromocytoma only and two patients with apparently sporadic extra-adrenal phaeochromocytoma was screened for SDHD and SDHB mutations. Secondly, for the study of SDHB in sporadic disease, tumour tissue from seven sporadic adrenal phaeochromocytomas, and three MEN 2-associated RETmutation-positive patients, previously shown to exhibit LOH at chromosome 1pter to 1p 34.3 (Benn et al., 2000) was examined for somatic SDHB mutations. In addition, 15 genomic samples from patients with sporadic adrenal phaeochromocytomas were tested for heterozygosity at the SDHB locus using the polymorphism IVS1-111G>A. LOH was determined by comparing matched blood and tumour pairs for those patients showing heterozygosity. The tumours showing LOH at this specific locus were then included in the analysis of SDHB mutations. DNA was extracted from blood and tumour tissue according to standard protocols. Patients gave informed consent according to a protocol approved by the Royal North Shore Hospital Human Research Ethics Committee. The general terminology of 'extra-adrenal phaeochromocytoma' is applied to 'paraganglioma' of sympathetic nervous system origin, which includes retroperitoneal and thoracic phaeochromocytomas (Benn et al., 2002; Neumann et al., 2002) .
SDHD and SDHB analysis PCR and sequencing were used to screen SDHD and SDHB in the seven genomic samples from probands of five families and from two patients with apparently sporadic phaeochromocytomas. In addition, 11 sporadic adrenal phaeochromocytomas and phaeochromocytomas from three RET-mutation-positive patients were screened for SDHB mutations.
The primer pairs for amplification of each exon and flanking intronic sequences of SDHD were designed on the basis of the genomic sequence using the following GenBank Accession number: AB026906. The primers used to sequence SDHD (amplicon size given in brackets) were as follows: DNA (100 ng) was amplified using an MJ Peltier Thermal Cycler PTC-100 (MJ Research Inc., Watertown, MA, USA). AmpliTaq s DNA polymerase (Perkin-Elmer, Norwalk, CT, USA) was used for PCR amplification of all exons. The following PCR conditions were used, a denaturation step of 941C for 10 min, then 35 cycles of denaturation at 941C for 45 s, 551C annealing for 45 s (with the exception of exon 1 where 581C was used), followed by extension at 721C for 45 s and finishing with 721C for 10 min.
For PCR and sequencing of SDHB, the primer pairs for exon amplification were designed on the basis of genomic sequences using the following GenBank Accession numbers: AL049569, HSU17296, HSU17880, HSU17881, HSU17882. HSU17883, HSU17884, HSU17885 and HSU17886. The GenBank Accession number for SDHB cDNA is HSU17248. The primer sequences for SDHB were as follows: DNA (100 ng) was amplified using an MJ Peltier Thermal Cycler PTC-100 (MJ Research. Inc., Watertown, MA, USA). AmpliTaq s DNA polymerase (Perkin-Elmer, Norwalk, CT, USA) was used for all exons and in addition for exon 7 TaqStartt Antibody (Clontech Laboratories, Inc., Palo Alto, CA, USA) was also used. The following PCR conditions were employed, a denaturation step of 951C for 5 min, then 35 cycles of denaturation at 951C for 1 min, annealing at 601C for 1 min (exons 5, 7 and 8) or 611C for 1 min (exons 1, 3 and 4) or 621C for 1 min (exon 2), or 651C for 1 min (exon 6) followed by extension of 721C for 1 min, and then 721C for 10 min.
Prior to sequencing, PCR products were purified using the Gibco BRL Concertt Rapid PCR Purification System (Life Technologies Inc, Rockville, MD, USA). Direct sequencing of these products was performed by Supamac (Sydney University, NSW, Australia) using ABI Prism BigDye Terminator v3.0 Ready Reaction Cycle Sequencing Kit (Applied Biosystems, Foster City, USA). Sephadex-purified cycle sequencing products were electrophoresed and analysed on a 3700 DNA Analyzer (Applied Biosystems, Perkin-Elmer Corp., USA).
Primer design for the detection of SDHB LOH
A forward primer, SDHB-2Fres, was designed to introduce a restriction site for the detection of the polymorphism IVS1-111G>A. The primer had the following sequence: 5 0 -GTATATCGACGGCCAGTGCCTTTTCTAAGAAGAT-TACGT-3 0 . The first 17 nucleotides of the primer correspond to the Ml3 forward sequencing primer (underlined) with the fourth and sixth nucleotides altered from an adenine (A) to a thymine (T) in order to prevent the formation of hairpin loop structures. At the 3 0 end of this primer, the third last nucleotide has been altered from a T (thymine) to a C (cytosine) in order to generate the restriction site (TACkGTA) for the enzyme Eco1051 (Fermentas Inc., Hanover, MD, USA), which cuts in the presence of the A allele. If germline DNA from a patient was heterozygous for the polymorphism IVS1-111G>A, DNA from paired tumour tissue was assessed for loss of one SDHB allele using the same marker, and when LOH was evident, the patient was included in the analysis of SDHB mutations in sporadic phaeochromocytomas.
RT-PCR and LOH
Total RNA was isolated from the tumour tissue of patient F06 using TriReagent s -RNA/DNA/Protein Isolation Reagent (Molecular Research Center Inc., Cincinnati, OH, USA) according to the manufacturer's protocol. cDNA was synthesised using SUPERSCRIPT II Preamplification System, for first strand cDNA synthesis (Life Technologies Inc., Rockville, MD, USA). The primers used for cDNA amplification were RT-F, 5 0 -GTGGTCGCACTCTCCTTGAG-3 0 and RT-R, 5 0 -AGGTTGGTGTCAATCCTTCG-3 0 . The expected product size was 353 bp, including the 3 0 end of exon 1, exons 2 and 3, and 5 0 end of exon 4. The PCR conditions used were the same as for SDHB exon 2 but at 631C. In addition LOH analysis was performed for this sample using 10 markers from 1pter to 1p34.3 as previously described (Benn et al., 2000) .
Note added in proof Subsequent to our submission of this manuscript the SDHB mutation R46Q was reported in the germline of a patient with an apparently sporadic malignant phaeochromocytoma (Gimenez-Roqueplo et al., 2002) .
